Skip to content

Diagnosis of Microaspiration in Intubated Critically Ill Patients: Pepsin vs 99m Technetium

Diagnosis of Microaspiration in Intubated Critically Ill Patients: Pepsin vs 99m Technetium

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02169193
Enrollment
0
Registered
2014-06-23
Start date
2015-09-30
Completion date
2017-01-31
Last updated
2015-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness

Keywords

microaspiration, mechanical ventilation, enteral feeding, 99m technetium, pepsin

Brief summary

Microaspiration of contaminated oropharyngeal secretions and gastric contents frequently occurs in intubated critically ill patients, and plays a major role in the pathogenesis of ventilator-associated pneumonia. Quantitative pepsin measurement in tracheal aspirates would be useful in diagnosing microaspiration of gastric contents in intubated critically ill patients. Technetium 99m labelled enteral feeding is the gold standard for the diagnosis of microaspiration. The investigators hypothesized that tracheal pepsin measurement is a good diagnosis marker of microaspiration compared to the gold standard.

Detailed description

Microaspiration of contaminated oropharyngeal secretions and gastric contents frequently occurs in intubated critically ill patients, and plays a major role in the pathogenesis of ventilator-associated pneumonia Quantitative pepsin measurement in tracheal aspirates would be useful in diagnosing microaspiration of gastric contents in intubated critically ill patients Technetium 99m labelled enteral feeding is the gold standard for the diagnosis of microaspiration. We hypothesized that tracheal pepsin measurement is a good diagnosis marker of microaspiration compared to the gold standard

Interventions

RADIATION99mTc-Rhenium Sulfide Nanocolloid

12 MBq of NanoCis added to 500 ml of enteral feeding

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \> or = 18 years * hospitalised in ICU * tracheal intubation using a polyvinyl chloride tube and mechanical ventilation * predictable mechanical ventilation \> or = 6 hours after inclusion * enteral nutrition by a nasogastric tube

Exclusion criteria

* refuse to participate to the study * no informed consent * pregnant * contra-indication for enteral nutrition * tracheotomy * intubation or re-intubation done in 6 hours preceding the inclusion

Design outcomes

Primary

MeasureTime frameDescription
incidence of pepsin levels ≥200 ng / mlfrom the start to 6 hours after beginning of 99m technetium labelled enteral feedingSensibility and sensitivity of Pepsin for the diagnosis of microaspiration will be determined with regard to 99m technetium (gold standard).

Secondary

MeasureTime frameDescription
likelihood ratio of pepsin of microregurgitationfrom the start to 6 hours after beginning of 99m technetium labelled enteral feedingSensibility and sensitivity of Pepsin for the diagnosis of microregurgitation will be determined with regard to 99m technetium.
likelihood ratio of pepsin of microaspirationfrom the start to 6 hours after beginning of 99m technetium labelled enteral feedingpositive and negative predictive values, positive and negative likelihood ratio of pepsin for the diagnosis of microaspiration compared to the 99m technetium (gold standard)
Youden Indexfrom the start to 6 hours after beginning of 99m technetium labelled enteral feedingYouden Index and ROC curve analysis of the Pepsin as a marker for the diagnosis of microaspiration compared to the 99m Technetium (gold standard)
ROC curvefrom the start to 6 hours after beginning of 99m technetium labelled enteral feedingYouden Index and ROC curve analysis of the Pepsin as a marker for the diagnosis of microaspiration compared to the 99m Technetium (gold standard)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026